DiscGenics Receives FDA Fast Track Designation for Cell Therapy

FDA granted DiscGenics a Fast Track designation for its investigational injectable disc cell therapy, IDCT, currently undergoing clinical trials in the U.S. and Japan for the reduction in pain and disability associated with degenerative disc disease. Companies can apply for Fast Track once they have sufficient preclinical and clinical evidence...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us